STAA
STAAR Surgical Company
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$23.47
−0.45%Year over year
Reported trailing growth
- Revenue
- +51.3%
- EBITDA
- +143.8%
- EBIT
- +132.0%
- EPS
- +104.1%
- Free cash flow
- +74.1%
- Operating cash flow
- +88.6%
Forward estimates
Based on analyst estimates
- Revenue
- +3.5%
- EBITDA
- +12.2%
- EPS
- +429.6%
Three-year CAGR
- Revenue
- -5.6%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jul 1, 2026